Skip to main content
CYDY logo

CytoDyn Inc. (CYDY) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.23 +$0.005 (+2.22%) |CouncilSplit View · 54 · B
MCap: $338M| Vol: 576.2K|

Market cap $338M is the value of all shares combined. Beta 1.27: the stock has moved about 27% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

CytoDyn Inc. (CYDY) trades at $0.23. CytoDyn Inc. is a clinical-stage biotechnology company focused on developing treatments for various therapeutic indications, primarily centered around its drug candidate, leronlimab. Market cap: $338M, Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing treatments for various therapeutic indications, primarily centered around its drug candidate, leronlimab. The company is currently navigating the complexities of clinical trials and regulatory approvals in the competitive biotechnology landscape.

Analyst Coverage for CYDY: CYDY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

Council Score · Weighted Average of 3 Disciplines
Split View 54/100 · B

CYDY: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Neutral read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

CytoDyn Inc. (CYDY) Healthcare & Pipeline Overview

Employees14
HeadquartersVancouver, United States

CytoDyn Inc. is a clinical-stage biotechnology firm specializing in the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Its focus areas include COVID-19, oncology (metastatic triple-negative breast cancer and micro-satellite stable colorectal cancer), and collaborations like the one with Creatv Bio, positioning it within the competitive biotechnology sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for CYDY?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

CytoDyn Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely dependent on the successful clinical development and regulatory approval of leronlimab. Key value drivers include positive Phase 2 trial results for its oncology programs and potential partnerships for commercialization. The company's beta of 1.27 indicates higher volatility compared to the market. A significant risk factor is the company's reliance on a single drug candidate and the inherent uncertainty of clinical trials. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's progress. As of 2026-03-16, the company's market capitalization is $338M, reflecting investor sentiment and expectations regarding future success.

Based on FMP financials and quantitative analysis

CYDY Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

CytoDyn Inc. is focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor.

  • Leronlimab is currently in Phase 2 clinical development for micro-satellite stable colorectal cancer and solid tumors, including metastatic triple-negative breast cancer.
  • The company has a collaboration with Creatv Bio to advance its research and development efforts.
  • CytoDyn's market capitalization is $338M as of 2026-03-16, reflecting investor sentiment.
  • The company's beta of 1.27 indicates higher volatility compared to the market.

Who Are CYDY's Competitors?

CYDY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
PLX Protalix BioTherapeutics, Inc. $3.02 +4.86% $255M 90 5-pillar
FENC Fennec Pharmaceuticals Inc. $13.33 -1.84% $471M 91 5-pillar
INDP Indaptus Therapeutics, Inc. $3.13 -4.86% $481M 60 5-pillar
HELP Cybin Inc. $6.78 -1.60% $541M 60 5-pillar
CLYM Climb Bio, Inc. $9.30 -4.91% $546M 68 5-pillar
ZVRA Zevra Therapeutics, Inc. $9.28 -1.28% $552M 91 5-pillar
CGEN Compugen Ltd. $1.96 -2.97% $186M 69 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYDY's Key Strengths?

Novel therapeutic approach targeting the CCR5 receptor.

  • Potential applications in multiple therapeutic areas.
  • Collaboration with Creatv Bio.

What Are CYDY's Weaknesses?

Reliance on a single drug candidate.

  • Limited financial resources.
  • High risk of clinical trial failure.

What Could Drive CYDY Stock Higher?

Phase 2 clinical trial results for micro-satellite stable colorectal cancer (timeline unknown).

  • Phase 2 clinical trial results for metastatic triple-negative breast cancer (timeline unknown).
  • Potential for new partnerships and collaborations.
  • Regulatory updates regarding leronlimab's development.

What Are the Key Risks for CYDY?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

  • Clinical trial failures for leronlimab.
  • Regulatory delays or rejection of leronlimab.
  • Competition from established pharmaceutical companies.
  • Limited financial resources and dependence on external funding.
  • Patent expiration and intellectual property challenges.

What Are the Growth Opportunities for CYDY?

  • Expansion into New Oncology Indications: CytoDyn has the opportunity to expand the application of leronlimab into additional oncology indications beyond micro-satellite stable colorectal cancer and metastatic triple-negative breast cancer. This could involve targeting other solid tumors or hematological malignancies. The oncology drug market is projected to reach $250 billion by 2030, offering a substantial market opportunity for successful therapies. This expansion would require further clinical trials and regulatory approvals, with a potential timeline of 3-5 years.
  • Partnerships and Collaborations: CytoDyn can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of leronlimab. These partnerships could provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, with deal values reaching billions of dollars annually. A successful partnership could significantly enhance CytoDyn's market position and financial resources, with potential deals materializing within the next 1-2 years.
  • Advancement of COVID-19 Program: Although the COVID-19 pandemic has subsided, CytoDyn could explore potential applications of leronlimab in treating long-term COVID-19 symptoms or other viral infections. The long-COVID market is still emerging, but some analysts estimate it could reach billions of dollars in the coming years. This would require additional clinical trials and regulatory approvals, with a potential timeline of 2-4 years.
  • Geographic Expansion: CytoDyn can expand its clinical trials and commercialization efforts into new geographic regions, particularly in Asia and Europe, where there is a growing demand for innovative cancer therapies. The global oncology market is expanding rapidly, with emerging markets offering significant growth opportunities. This expansion would require regulatory approvals and partnerships with local distributors, with a potential timeline of 3-5 years.
  • Leveraging Orphan Drug Designation: CytoDyn can seek orphan drug designation for leronlimab in specific rare cancer subtypes. Orphan drug designation provides several benefits, including market exclusivity and tax incentives, which can enhance the commercial viability of the drug. The orphan drug market is growing faster than the overall pharmaceutical market, driven by unmet medical needs and regulatory support. This designation could be pursued within the next 1-2 years, depending on the specific cancer subtype targeted.

What Are CYDY's Competitive Advantages?

  • Patent protection for leronlimab (limited information available).
  • Clinical data supporting the efficacy of leronlimab (limited information available).
  • Strategic collaborations with research institutions and other companies.

What Does CYDY Do?

CytoDyn Inc., formerly RexRay Corporation, was founded in 2002 and is headquartered in Vancouver, Washington. It operates as a clinical-stage biotechnology company dedicated to developing innovative treatments for a range of therapeutic indications. The company's primary focus is on the clinical development of leronlimab, a humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). Leronlimab is being investigated for its potential in treating COVID-19, micro-satellite stable colorectal cancer, and solid tumors, including metastatic triple-negative breast cancer. CytoDyn's approach involves strategic collaborations, such as its partnership with Creatv Bio, to advance its research and development efforts. The company is currently in Phase 2 clinical development for several of its oncology programs. CytoDyn aims to address unmet medical needs through its targeted therapies, navigating the complex regulatory landscape to bring its products to market.

What Products and Services Does CYDY Offer?

  • Develops leronlimab, a humanized monoclonal antibody.
  • Targets the CCR5 receptor for therapeutic intervention.
  • Conducts clinical trials for COVID-19 treatment.
  • Investigates leronlimab for micro-satellite stable colorectal cancer.
  • Explores leronlimab's potential in treating metastatic triple-negative breast cancer.
  • Collaborates with Creatv Bio for research and development.

How Does CYDY Make Money?

  • Focuses on developing and commercializing leronlimab.
  • Generates revenue through potential future sales of leronlimab.
  • Relies on partnerships and collaborations for funding and expertise.

What Industry Does CYDY Operate In?

CytoDyn Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for oncology drugs is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like CytoDyn are striving to develop novel therapies that address unmet medical needs. The success of biotechnology companies depends on their ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy. The biotechnology industry is subject to rapid technological advancements and evolving scientific understanding, requiring companies to remain innovative and adaptable.

Who Are CYDY's Key Customers?

  • Patients with COVID-19 (potential future market).
  • Patients with micro-satellite stable colorectal cancer (clinical trial participants).
  • Patients with metastatic triple-negative breast cancer (clinical trial participants).
Model self-rating on this text: 59% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
ROE 53%

Key Financial Metrics

Return on equity for CytoDyn Inc. stands at 52.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.38 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.2%, the inverse of the P/E and a quick read on earnings relative to price.

CytoDyn Inc. (CYDY) Valuation Context

Valued at $338M, CYDY is classified as a small-cap stock.

Company Profile

CytoDyn Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, United States.

F-Score 3/9

Financial Health

CytoDyn Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

4/5 beats

Earnings Track Record

CytoDyn Inc. has beaten Wall Street's EPS estimate in 4 of its last 5 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.8% above estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project CytoDyn Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.20.

Insider Activity

12 transactions · 0 purchases, 0 sales, 12 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

CYDY Financials

Bull Case vs Bear Case

Bull Case

  • Novel therapeutic approach targeting the CCR5 receptor.
  • Potential applications in multiple therapeutic areas.
  • Collaboration with Creatv Bio.
  • Upcoming: Phase 2 clinical trial results for micro-satellite stable colorectal cancer (timeline unknown).

Bear Case

  • Reliance on a single drug candidate.
  • Limited financial resources.
  • High risk of clinical trial failure.
  • Potential: Clinical trial failures for leronlimab.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

CYDY Latest News

CYDY Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CYDY.

Price Targets

Wall Street price target analysis for CYDY.

CYDY MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CYDY; grades run from A+ (80-100) to F (below 30).

CYDY OTC Market Information

The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market, designed for developing companies. Unlike the NYSE or NASDAQ, OTCQB companies have more lenient listing requirements, making it accessible for smaller or early-stage businesses. To qualify for OTCQB, companies must meet minimum financial standards, follow SEC reporting guidelines (or the Pink Basic Disclosure Guidelines if they are not SEC reporting), and undergo an annual verification process. This tier offers more visibility and credibility compared to the lower OTC Pink market but less than the major exchanges.

  • OTC Tier: OTC Other
Liquidity: Trading volume for CYDY on the OTCQB market can be highly variable and generally lower than on major exchanges. This can lead to wider bid-ask spreads and increased price volatility. Investors may experience difficulty in buying or selling large quantities of shares without significantly impacting the price. It is crucial to assess the average daily trading volume and bid-ask spread before investing to understand the potential liquidity risks.
OTC Risk Factors:
  • Limited regulatory oversight compared to major exchanges.
  • Lower liquidity and higher price volatility.
  • Potential for less stringent financial reporting requirements.
  • Increased risk of fraud or manipulation.
  • Dependence on a single drug candidate.
Due Diligence Checklist:
  • Verify the company's financial disclosures on the OTC Markets website.
  • Review the company's SEC filings (if applicable).
  • Assess the company's management team and their track record.
  • Evaluate the company's clinical trial data and regulatory prospects.
  • Analyze the company's competitive landscape and market potential.
  • Monitor the company's news releases and investor relations materials.
  • Understand the risks associated with investing in OTCQB-listed companies.
Legitimacy Signals:
  • OTCQB listing indicates a certain level of financial and reporting compliance.
  • Collaboration with Creatv Bio suggests external validation of the company's technology.
  • Clinical trials underway for leronlimab indicate ongoing research and development efforts.

CytoDyn Inc. Healthcare Stock: Key Questions Answered

Is CYDY a good stock to buy?

Stock Expert AI does not rate CYDY buy, sell or hold. CytoDyn Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CYDY stock price today?

The last price recorded on this page for CytoDyn Inc. (CYDY) is $0.23, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about CYDY stock?

As of 2026-03-16, formal analyst coverage of CYDY stock is limited due to its OTCQB listing and clinical-stage nature. However, investor sentiment and valuation are primarily driven by the progress of leronlimab's clinical trials and regulatory prospects.

What are the key factors to evaluate for CYDY?

Evaluate CYDY on fundamentals, analyst consensus, and risk factors. A significant risk factor is the company's reliance on a single drug candidate and the inherent uncertainty of clinical trials. Not financial advice.

How frequently does CYDY data refresh on this page?

CYDY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CYDY's recent stock price performance?

CytoDyn Inc. (CYDY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting the CCR5 receptor. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CYDY overvalued or undervalued right now?

CytoDyn Inc. (CYDY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CYDY before investing?

Before investing in CytoDyn Inc. (CYDY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PLX · Protalix BioTherapeutics, Inc. · 90 /100
  • FENC · Fennec Pharmaceuticals Inc. · 91 /100
  • INDP · Indaptus Therapeutics, Inc. · 60 /100

See all scored stocks →

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on specific financial metrics and analyst coverage.
  • OTC listing increases investment risk.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives